Unaudited NAV for November 2023
Arix Bioscience PLC (ARIX)
Unaudited NAV for November 2023
13-Dec-2023 / 07:00 GMT/BST
Arix Bioscience plc
Unaudited NAV for November 2023
LONDON, 13 December 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 30 November 2023 as follows:
Date
NAV Breakdown
Total NAV
NAV per share
Listed Portfolio
Unlisted Portfolio
Cash
Other Interests
30 November 2023
(unaudited)
£54.3m
£66.4m
£105.8m
£2.6m
£229.1m
£1.77
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt
Sarah MacLeod, Nick Johnson, Molly Ring
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
ISIN: GB00BD045071 Category Code: MSCM TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 291541 EQS News ID: 1795525
End of Announcement EQS News Service